Qianjin Pharmaceutical: Subsidiary Qianjin Xiangjiang Pharmaceutical obtains the registration certificate for Risperidone Hydrochloride Tablets.

Qianjin Pharmaceutical announced that its subsidiary, Qianjin Xiangjiang Pharmaceutical, has received the "Drug Registration Certificate" for Risperidone Hydrochloride Tablets issued by the National Medical Products Administration. This drug is used to treat schizophrenia, and other domestic enterprises that have obtained the drug registration certificate include Jiangsu Haosen Pharmaceutical Group Co., Ltd., Zhejiang Haizheng Pharmaceutical Co., Ltd., and Zhenzhong Tianqing Pharmaceutical Group Co., Ltd. Qianjin Xiangjiang Pharmaceutical has accumulated research and development investment of 6.3294 million yuan for Risperidone Hydrochloride Tablets. The approval of the drug registration certificate for Risperidone Hydrochloride Tablets is equivalent to passing consistency evaluation, further enriching the company's product pipeline and benefiting the sustainable development of the company. However, the production and sales of drugs are easily affected by factors such as changes in national policies and market environment, and have a high level of uncertainty.